Prof Lemmens underscores large unmet medical need in intracerebral hemorrhage “Very encouraging” data from Phase 2a trial with lead asset BIOX-101 Bioxodes is preparing for a possibly registrational ...

Bioceres Crop (BIOX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.09 per share a year ago. These figures are ...

Gosselies, Belgium, 11 September 2025 (08:30 am CET) – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and ...

Fourth Quarter Revenue: $74.7 million, a 40% decline year-over-year. Full Year Revenue: $335.3 million, down 28% year-over-year. Crop Protection Revenue: $181.9 million for the full year, down 20% ...

Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces promising interim results from ...

Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations ...

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) stock has reached a 52-week low, dipping to $5.41, as investors navigate a turbulent market environment. According to InvestingPro data, the stock has ...

Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has enrolled the first 16 of 32 patients in ...

Metso is extending its hydrometallurgy offering with the launch of OKTOP ® BIOX ® Reactor. The reactor is ideal for the pre-treatment of refractory gold concentrate and base metal leaching. It is part ...

We recently compiled a list of the 8 Best Fertilizer Stocks To Buy Now. In this article, we are going to take a look at where Bioceres Crop Solutions Corp. (NASDAQ:BIOX) stands against the other ...